Kwality Pharmaceuticals Appoints Dr. Bedi as Independent Director Under Regulation 30

Kwality Pharmaceuticals Limited has officially appointed Dr. PreetMohinder Singh Bedi as Additional Independent Director, effective January 1, 2026. The appointment was approved by the Board of Directors during their meeting held on January 1, 2026, following the recommendation of the Nomination and Remuneration Committee, as disclosed under Regulation 30 of SEBI Listing Regulations.

Appointment Details and Regulatory Compliance

Dr. Bedi will serve as Additional Independent Director for a period of five consecutive years, with his tenure running from January 1, 2026, to December 31, 2030. The appointment is subject to approval by the company's shareholders. The company has confirmed that Dr. Bedi satisfies the criteria of independence prescribed under the Companies Act, 2013 and SEBI Listing Regulations.

Parameter:	Details
Director Name:	Dr. PreetMohinder Singh Bedi
DIN:	11452004
Position:	Additional Independent Director
Term Duration:	5 years
Effective Date:	January 1, 2026
Term End Date:	December 31, 2030
Approval Status:	Subject to shareholder approval
BSE Scrip Code:	539997

Professional Background and Qualifications

Dr. PreetMohinder Singh Bedi brings extensive experience to the board, with over 28 years in the pharmaceutical industry. He currently serves as Professor in the Department of Pharmaceutical Sciences and Director of Global Ranking and International Collaboration Cell at Guru Nanak Dev University, Amritsar.

Dr. Bedi has achieved significant recognition in his field, being included in the 2025 Stanford-Elsevier list of the world's top 2% scientists for his lifetime research impact. His academic credentials include B-Pharmacy from Panjab University, Chandigarh, M-Pharmacy from Punjabi University, Patiala, and PhD from Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar.

Research and Academic Achievements

Dr. Bedi's research portfolio demonstrates substantial contributions to pharmaceutical sciences. He has authored over 150 scientific publications and holds patents in Medicinal Chemistry. His research focuses on drug design, synthesis, ADME studies, and biologically active molecules with antimicrobial, antidiabetic, anti-inflammatory, and anticancer activities.

Achievement Category:	Details
Industry Experience:	Over 28 years
Scientific Publications:	Over 150
Research Focus:	Drug design, synthesis, ADME studies
Recognition:	2025 Stanford-Elsevier top 2% scientists list
Fellowship:	Royal Society Fellowship (UK)
Award:	Best Educationist Award (2012)

Leadership and Administrative Roles

Dr. Bedi joined the Department of Pharmaceutical Sciences at Guru Nanak Dev University, Amritsar in 1997. Throughout his academic career, he has held several leadership positions, including serving as Head of the Department for more than eight years. He has also served as Dean Colleges and Dean Student Welfare at Guru Nanak Dev University, Amritsar.

He has led major research projects funded by prominent organizations including UGC, DST, CSIR, and AICTE. Additionally, he was selected by the Ministry of Health & Family Welfare, Government of India, for a national health research funding study.

Independence and Compliance Verification

Kwality Pharmaceuticals Limited has verified that Dr. Bedi is not debarred from holding the office of Director by virtue of any order passed by SEBI or any other authority. The company confirmed that Dr. Bedi is not related to any existing Director of the company, ensuring his independence in board matters. The appointment has been communicated to BSE Limited under the company's scrip code 539997.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.54%	-3.95%	+9.44%	-10.98%	+6.59%	+1,627.72%

Kwality Pharmaceuticals Ltd (KPL) has reported robust financial results for the first half of fiscal year 2026, demonstrating continued growth and operational strength.

Financial Highlights

KPL announced consolidated revenue of ₹224.00 crore for H1 FY26, representing a significant 32% year-on-year growth from ₹170.00 crore in H1 FY25. The company's EBITDA increased by 35% to ₹50.00 crore from ₹37.00 crore in the previous year, with margins improving to 22.50% from 22.00%. Net profit saw a substantial rise to ₹26.00 crore, up from ₹17.00 crore in the same period last year.

Operational Performance

The company's strong performance in H1 FY26 was driven by several factors:

Accelerated R&D initiatives, including multiple Bioequivalence and clinical trial programs across injectables and oral solid dosage segments.
Capital expenditure for Biologics, Oncology, and Hormone manufacturing facilities, funded through internal accruals.
Generation of approximately ₹30.00 crore cash surplus during the quarter.
Receipt of multiple new product registrations, expanding the company's portfolio.

Strategic Initiatives

KPL continues to focus on growth and expansion:

Ongoing investments in R&D and clinical initiatives to strengthen its product pipeline.
Expansion of manufacturing capabilities, particularly in high-value segments like Biologics and Oncology.
Construction and validation of a new Hormone manufacturing facility, enhancing the company's production capacity.

Future Outlook

Looking ahead, KPL maintains a positive outlook:

Management projects Q3 FY26 revenue of around ₹140.00 crore.
The company remains confident of exceeding the ₹500.00 crore revenue target for the full year.
Continued focus on improving operational efficiencies and maintaining strong profitability.

Kwality Pharmaceuticals' impressive H1 FY26 results and strategic initiatives position it well for sustained growth in the pharmaceutical sector.